DGAP-News: Apogenix Granted Orphan Designation by the European Commission for Asunercept to Treat Myelodysplastic Syndromes

Nachricht vom 05.10.2017 (www.4investors.de) -


DGAP-News: Apogenix AG / Key word(s): Miscellaneous

Apogenix Granted Orphan Designation by the European Commission for Asunercept to Treat Myelodysplastic Syndromes
05.10.2017 / 10:30


The issuer is solely responsible for the content of this announcement.
Apogenix Granted Orphan Designation by the European Commission for Asunercept to Treat Myelodysplastic Syndromes

Orphan designations facilitate the development and authorization of medicines for rare diseases, as assessed by the European Medicines Agency's (EMA) Committee for Orphan Medicinal Products

Heidelberg, Germany, October 05, 2017 - Apogenix AG, a biopharmaceutical company developing next-generation immuno-oncology therapeutics, announced today that its lead product candidate, asunercept (APG101), has been granted orphan designation from the European Commission (EC) for the treatment of myelodysplastic syndromes (MDS). MDS is a bone marrow disorder characterized by ineffective hematopoiesis (blood cell formation) and can lead to severe anemia. Patients often suffer from life-threatening infections and are at risk of developing acute myeloid leukemia.

Orphan designation includes access to a centralized marketing authorization procedure for the European Union, ten years of protection from market competition with similar medicines in similar indications and fee reductions for consultations with the EMA. Earlier, asunercept received Orphan Drug Designation for MDS from the US Food and Drug Administration (FDA).

Dr. Harald Fricke, Chief Medical Officer of Apogenix, commented: "The vast majority of patients suffering from MDS are anemic and dependent on frequent regular blood transfusions. Asunercept prevents premature death of red blood cells in the bone marrow and thus reduces the need of blood transfusions, even making them superfluous in many patients. We are highly encouraged by the data from our clinical phase I trial with asunercept in these patients and are currently preparing to initiate a clinical phase II proof-of-concept trial to further evaluate the efficacy of asunercept in MDS."

Asunercept has been evaluated in an open label, single-arm phase I clinical trial in 20 patients with low to intermediate risk MDS, in which treatment with asunercept was well tolerated and led to a significant decrease in transfusion frequency. In addition, investigation of parameters involved in erythropoiesis delineated how asunercept stimulates the production of red blood cells in these patients.

Asunercept binds to the CD95 ligand (CD95L) and blocks the activation of the CD95 receptor. Excessive stimulation of the CD95 receptor on hematopoietic precursor cells in the bone marrow of MDS patients inhibits erythropoiesis. As a result, transfusion-dependent anemia develops, which is refractory to erythropoiesis-stimulating agents. Treatment with asunercept, which inhibits the CD95 system, addresses this major cause of the disorder.

About Myelodysplastic Syndromes (MDS)
MDS is a bone marrow disorder that is characterized by ineffective hematopoiesis and can lead to severe anemia. In most cases, the anemia is treated with blood transfusions that eventually result in an iron overload, which can damage the liver and other organs. At the same time, the number of thrombocytes that are responsible for coagulation and the number of leucocytes that are responsible for immune defense significantly decreases in patients with this disorder. As a result, MDS patients frequently suffer from sudden bleeding and life-threatening infections. In addition, they are at risk of developing acute myeloid leukemia, a type of blood cancer.About asunercept (APG101)
Apogenix' lead immuno-oncology candidate asunercept is a fully human fusion protein that consists of the extracellular domain of the CD95-receptor and the Fc domain of an IgG1 antibody. Asunercept is being developed for the treatment of solid tumors and malignant hematological diseases. The World Health Organization (WHO) has assigned the international nonproprietary name (INN) "asunercept" for APG101.

About Apogenix
Apogenix is a private company developing innovative immuno-oncology therapeutics for the treatment of cancer and other malignant diseases. The company has built a promising pipeline of immuno-oncology drug candidates that target different tumor necrosis factor superfamily (TNFSF)-dependent signaling pathways, thereby restoring the immune response against tumors. Since its inception in 2005, Apogenix has raised more than 100 million euros in financing rounds, public grants, as well as upfront and milestone payments from licensing agreements. The company is based in Heidelberg, Germany.

Contact
Thomas Hoeger, Ph.D., CEO
Apogenix AG
Phone: +49 (6221) 58 60 80
Email: contact@apogenix.com
Web: www.apogenix.comMedia Contacts
Katja Arnold / Cora Kaiser, Ph.D.
MC Services AG
Phone: +49 (89) 210 228 0
Email: apogenix@mc-services.eu
 












05.10.2017 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de



616105  05.10.2017 





(Werbung)
PfeilbuttonOhne Depotgebühren. Mit Kosten-Airbag. Das Wertpapierdepot der MERKUR BANK.

4investors Exklusiv-Berichte und Interviews:
PfeilbuttonMensch und Maschine: „Auf Jahre hinaus noch genug Renditepotenziale“
PfeilbuttonStern Immobilien: In den attraktivsten Nischenmärkten Europas tätig
PfeilbuttonPNE Wind: Lesser sieht „attraktive Opportunitäten für Zukäufe“
PfeilbuttonIPO-Kandidat STEMMER IMAGING AG: „Wir wollen den europäischen Markt weiter konsolidieren“

Aktuelle Nachrichten aus der 4investors-Redaktion

22.02.2018 - wallstreet:online: Umsatz wird wohl verdoppelt - Gewinn soll deutlich steigen
22.02.2018 - Indus übertrifft eigene Erwartungen
22.02.2018 - VTG wird höhere Divdende zahlen
22.02.2018 - TAG Immobilien erhöht Dividende stärker als erwartet
22.02.2018 - Deutsche Industrie REIT legt Quartalszahlen vor
22.02.2018 - German Startups: Elgeti steigt ein
22.02.2018 - Fuchs Petrolub: Leichtes Plus bei der Dividende
22.02.2018 - Datron kündigt Dividendenzahlung an
22.02.2018 - Krones hält die Margen konstant
22.02.2018 - Lang + Schwarz sieht sich auch 2018 auf Rekordkurs - Dividende steigt


Chartanalysen

22.02.2018 - Steinhoff Aktie: Neue Verkaufssignale! Halten die Gläubiger still?
22.02.2018 - Evotec Aktie: Alles super?
22.02.2018 - Baumot Aktie: Heute wird es noch einmal spannend!
22.02.2018 - Paion Aktie erwacht aus dem Tiefschlaf - was passiert hier?
21.02.2018 - Aixtron Aktie: Durchbruch nach oben geschafft?
21.02.2018 - Medigene Aktie: Kein Tag für schlechte Nerven
21.02.2018 - Baumot Aktie profitiert von Daimler-News - Kaufsignal
21.02.2018 - Evotec Aktie: Kommt die Kursrallye wirklich?
21.02.2018 - 4SC Aktie: Das Ende der Kursparty?
20.02.2018 - Aumann Aktie: Kaufsignal und TecDAX-Phantasie


Analystenschätzungen

22.02.2018 - Bet-at-home: Ziele erreichbar
22.02.2018 - PNE Wind: Weitere Fortschritte
22.02.2018 - Xing: Unter dem Konsens
22.02.2018 - Volkswagen: Was für ein Kursziel
22.02.2018 - Deutsche Telekom: Neues Kursziel nach den Quartalszahlen
22.02.2018 - Deutsche Telekom: Uneinigkeit bei den Analysten
22.02.2018 - Hochtief: Keine Verkaufsempfehlung mehr
22.02.2018 - Gerry Weber: Analysten reduzieren Erwartungen deutlich
22.02.2018 - Aixtron: Verkaufen vor den Zahlen
22.02.2018 - Adidas: Doppelte Hochstufung


Kolumnen

22.02.2018 - ifo-Geschäftsklima sinkt deutlich – Wirtschaft startet aber schwungvoll ins Jahr - Nord LB Kolumne
22.02.2018 - ifo Index: Rückgang, aber es gibt kein Grund zur Sorge - VP Bank Kolumne
22.02.2018 - Einkaufsmanagerindizes geben stärker als erwartet nach - Commerzbank Kolumne
22.02.2018 - DAX mit schwachem Stand: „Long-Legged-Doji“ - Donner + Reuschel Kolumne
22.02.2018 - ThyssenKrupp Aktie: Der Abwärtstrend könnte sich fortsetzen - UBS Kolumne
22.02.2018 - DAX: Warten auf frische Impulse - UBS Kolumne
21.02.2018 - Ende der Schönwetterperiode – Sarasin Kolumne
21.02.2018 - Aufbruchsstimmung in Südafrika - Commerzbank Kolumne
21.02.2018 - BASF Aktie: Weiteres Erholungspotenzial vorhanden - UBS Kolumne
21.02.2018 - DAX: Neuer Anlauf auf 12.500-Punkte-Widerstand - UBS Kolumne

Werbung

All Right Reserved by minimalthemes - ©2018 Stoffels & Barck GbR